Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes

Roberto Pecoits-Filho*, Ikechi G. Okpechi, Jo Ann Donner, David C.H. Harris, Harith M. Aljubori, Aminu K. Bello, Ezequiel Bellorin-Font, Fergus J. Caskey, Allan Collins, Alfonso M. Cueto-Manzano, John Feehally, Bak Leong Goh, Kitty J. Jager, Masaomi Nangaku, Muhibur Rahman, Manisha Sahay, Abdulkarim Saleh, Laura Sola, Rumeyza Turan Kazancioglu, Rachael C. WalkerRobert Walker, Qiang Yao, Xueqing Yu, Ming Hui Zhao, David W. Johnson

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

53 Citations (Scopus)
109 Downloads (Pure)

Abstract

A large gap between the number of people with end-stage kidney disease (ESKD) who received kidney replacement therapy (KRT) and those who needed it has been recently identified, and it is estimated that approximately one half to three quarters of all people with ESKD in the world may have died prematurely because they could not receive KRT. This estimate is aligned with a previous report that estimated that more than 3 million people in the world died each year because they could not access KRT. In this article, we discuss the reasons for the differences in treated and untreated ESKD, KRT modalities and outcomes, and present strategies to close the global KRT gap by establishing robust health information systems to guide resource allocation to areas of need, inform KRT service planning, enable policy development, and monitor KRT health outcomes.
Original languageEnglish
Pages (from-to)e3-e9
Number of pages7
JournalKidney International Supplements
Volume10
Issue number1
Early online date19 Feb 2020
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • end-stage kidney disease
  • global health
  • health information systems
  • health services accessibility
  • registries
  • kidney replacement therapy

Fingerprint

Dive into the research topics of 'Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes'. Together they form a unique fingerprint.

Cite this